Skip to main content
Clinical Trials/NCT01625273
NCT01625273
Completed
Not Applicable

Supplementation of Infant Formula With the Synbiotics (Lactobacillus Paracasei Ssp. Paracasei Strain F19 and Fructo- and Galactooligosaccharides).

Arla Foods1 site in 1 country182 target enrollmentStarted: January 2010Last updated:
ConditionsInfant Formula

Overview

Phase
Not Applicable
Status
Completed
Sponsor
Arla Foods
Enrollment
182
Locations
1
Primary Endpoint
Growth (body weight, length, head circumference)

Overview

Brief Summary

The primary hypothesis is that Lactobacillus paracasei ssp. paracasei strain F19 in an infant formula containing FOS/GOS is safe and tolerable for use in infants from 0 to 6 months.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
1 Day to 28 Days (Child)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • healthy infants of mothers who voluntarily resigned completely from breastfeeding
  • infant age 28 days
  • delivered between 38 and 42 weeks of gestation
  • vaginal delivery
  • birth weight \> 2700 g and \< 4200 g
  • parent or the subject's legal representative has to speak and understand Polish

Exclusion Criteria

  • fully or partially breastfed infants
  • malformations, handicaps or congenital diseases that could affect normal growth
  • treatment with antibiotics
  • fed infant formula with pre- and/or probiotics

Outcomes

Primary Outcomes

Growth (body weight, length, head circumference)

Time Frame: From 28 days to 6 months

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Arla Foods
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials